JP2011510935A - Novel ointment to promote skin activation and ulcer healing - Google Patents
Novel ointment to promote skin activation and ulcer healing Download PDFInfo
- Publication number
- JP2011510935A JP2011510935A JP2010544583A JP2010544583A JP2011510935A JP 2011510935 A JP2011510935 A JP 2011510935A JP 2010544583 A JP2010544583 A JP 2010544583A JP 2010544583 A JP2010544583 A JP 2010544583A JP 2011510935 A JP2011510935 A JP 2011510935A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- ointment
- substance
- alpha
- delta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002674 ointment Substances 0.000 title claims abstract description 19
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 8
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 8
- 230000035876 healing Effects 0.000 title claims description 7
- 230000004913 activation Effects 0.000 title 1
- 230000037303 wrinkles Effects 0.000 claims abstract description 26
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- 241000283690 Bos taurus Species 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000000004 hemodialysis solution Substances 0.000 claims abstract description 7
- 230000002085 persistent effect Effects 0.000 claims abstract description 7
- 239000004264 Petrolatum Substances 0.000 claims abstract description 6
- 229940066842 petrolatum Drugs 0.000 claims abstract description 6
- 235000019271 petrolatum Nutrition 0.000 claims abstract description 6
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims abstract description 6
- 230000003779 hair growth Effects 0.000 claims abstract description 5
- 239000000126 substance Substances 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims description 5
- 235000019489 Almond oil Nutrition 0.000 claims description 5
- 239000008168 almond oil Substances 0.000 claims description 5
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 239000003205 fragrance Substances 0.000 claims description 5
- 239000012188 paraffin wax Substances 0.000 claims description 5
- 229930003799 tocopherol Natural products 0.000 claims description 5
- 239000011732 tocopherol Substances 0.000 claims description 5
- 125000002640 tocopherol group Chemical class 0.000 claims description 5
- 235000019149 tocopherols Nutrition 0.000 claims description 5
- 229930003802 tocotrienol Natural products 0.000 claims description 5
- 239000011731 tocotrienol Substances 0.000 claims description 5
- 229940068778 tocotrienols Drugs 0.000 claims description 5
- 235000019148 tocotrienols Nutrition 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 6
- 102000008186 Collagen Human genes 0.000 abstract description 5
- 108010035532 Collagen Proteins 0.000 abstract description 5
- 229940087168 alpha tocopherol Drugs 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 abstract description 5
- 229960000984 tocofersolan Drugs 0.000 abstract description 5
- 235000004835 α-tocopherol Nutrition 0.000 abstract description 5
- 239000002076 α-tocopherol Substances 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 230000002407 ATP formation Effects 0.000 abstract description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 abstract description 2
- 230000006706 cellular oxygen consumption Effects 0.000 abstract description 2
- 210000001126 granulation tissue Anatomy 0.000 abstract description 2
- 230000000302 ischemic effect Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 47
- 206010040954 Skin wrinkling Diseases 0.000 description 24
- 238000000034 method Methods 0.000 description 7
- 239000003925 fat Substances 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 5
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003883 ointment base Substances 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229940089093 botox Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000004492 retinoid derivatives Chemical class 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- FAIXYKHYOGVFKA-UHFFFAOYSA-N Kinetin Natural products N=1C=NC=2N=CNC=2C=1N(C)C1=CC=CO1 FAIXYKHYOGVFKA-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 229940094657 botulinum toxin type a Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical compound N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 229960001669 kinetin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000005488 sandblasting Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037366 wrinkle cream Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
【解決手段】 本発明は、ビタミンＥ特にアルファ−トコフェロールと、化学的及び生物学的に標準化された健康的な若いウシのタンパク質を含まない血液透析物を含む軟膏に係るものである。これは、細胞の酸素消費を刺激し、ＡＴＰ合成を刺激し、虚血組織を血行再建することはもちろんのこと、可逆細胞及び保護組織の損傷からの回復を加速させ、コラーゲン合成及び新しい肉芽組織の成長を促進し、再生を加速させる。担体として、軟膏は油性溶液中のワセリン（７０％）を含む。低濃度の軟膏は、皮膚を再生し、しわを減らす能力を有する。高濃度の軟膏は、髪の成長を刺激し、持続性潰瘍の治療を促進する能力を有する。
【選択図】 なし
The present invention relates to an ointment comprising vitamin E, in particular alpha-tocopherol, and a hemodialysate free of chemically and biologically standardized healthy young bovine proteins. It stimulates cellular oxygen consumption, stimulates ATP synthesis, accelerates recovery from damage to reversible cells and protective tissues as well as revascularizes ischemic tissues, collagen synthesis and new granulation tissue Promote growth and accelerate regeneration. As a carrier, the ointment contains petrolatum (70%) in an oily solution. Low concentration ointments have the ability to regenerate skin and reduce wrinkles. High concentrations of ointment have the ability to stimulate hair growth and promote the treatment of persistent ulcers.
[Selection figure] None
Description
特に顔と首の皮膚おけるしわは、頭髪の脱毛とともに、年を重ねたヒトの問題となっている。医学的なものであれ、外科的なものであれ、多くの処置が上記の症例を治療するものとして様々な成功率とともに説明されているが、未だこの分野には新しい薬や処置のための余地が含まれている。 Wrinkles on the skin of the face and neck, in particular, have become a problem for older humans along with hair loss. Many treatments, whether medical or surgical, have been described with various success rates as treating the above cases, but there is still room for new drugs and treatments in this area. It is included.
また、持続性潰瘍は、適切な治療を見つけることが問題となることもある。治療に有効な方法は、このような症例に優位性をもつ。 Persistent ulcers can also be problematic in finding appropriate treatments. Effective treatment methods have an advantage in such cases.
皮膚の高齢化による影響（しわ、乾燥）を妨げるために、多くの外科的手順及び種々の局所用の薬剤が使用されてきた。 Many surgical procedures and various topical agents have been used to prevent the effects of skin aging (wrinkles, dryness).
薬剤
局所用レチノイド。ビタミンＡ誘導体であり、レチノイドは、皮膚に使用すると、皮膚の細かいしわ、しみ及び肌荒れを元の状態に回復させることができる場合がある。レチノイドは、より簡単に皮膚隆起を起こしやすくなるので、日焼け止め及び防護服を含むスキンケアプログラムと共に使用される必要がある。レチノイドは、赤み、乾燥、かゆみ、及び火傷又はちりちりした感じを引き起こす可能性がある。
Drug
Topical retinoid. It is a vitamin A derivative, and when used on the skin, the retinoid may be able to restore fine wrinkles, blemishes and rough skin to the original state. Retinoids need to be used with skin care programs, including sunscreen and protective clothing, because they are more easily prone to skin bulges. Retinoids can cause redness, dryness, itching, and burns or a dusty feel.
処方箋の必要のないしわクリーム。しわ取りクリームの効果は、一部の活性成分又は成分に依存する。レチノール、アルファヒドロキシ酸、カイネチン、コエンザイムＱ１０、銅ペプチド、及び抗酸化物質は、しわをわずかに改善することがある。 Wrinkle cream that does not require a prescription. The effect of the wrinkle removal cream depends on some active ingredients or ingredients. Retinol, alpha hydroxy acid, kinetin, coenzyme Q10, copper peptides, and antioxidants may improve wrinkles slightly.
外科的処置及び他の技術
様々な皮膚のリサーファシング技術（ｒｅｓｕｒｆａｃｉｎｇ ｔｅｃｈｎｉｑｕｅｓ）、注射、注入用製剤及び外科的処置は、しわを伸ばすことができる。それぞれの働きはわずかに異なり、それぞれに独自の潜在的な結果及び副作用がある。
Surgical procedures and other techniques
Various skin resurfacing techniques, injections, infusion formulations and surgical procedures can stretch wrinkles. Each function is slightly different and each has its own potential consequences and side effects.
皮膚切除。この処置は、高速回転ブラシで皮膚の表面層を削ること（プレーニング）から成る。このプレーニングは、皮膚の表面及びその場所で増大した皮膚の新しい層を除去する。発赤、痂皮形成及び腫れは、一般的に二週間続く。赤みがひき、望んでいた結果の肌を見るのに数カ月かかることもある。 Skin resection. This procedure consists of scraping the surface layer of the skin (planing) with a high speed rotating brush. This planing removes a new layer of skin that has grown on and at the surface of the skin. Redness, crust formation and swelling generally last for two weeks. It may take months to see the skin with redness and the desired result.
マイクロダーマブレーション（Ｍｉｃｒｏｄｅｒｍａｂｒａｓｉｏｎ）。この技術は皮膚切除と似ているが、表皮の切除がわずかですむ。これは、酸化アルミニウムの結晶を、基本的には肌にサンドブラスト（ｓａｎｄｂｌａｓｔ）しながら、顔の上に真空吸引を使用して行われている。マイクロダーマブレーションは、通常、わずかで一時的な結果を維持するために、繰り返し治療を要する。 Microdermabrasion. This technique is similar to skin resection, but requires only a small resection of the epidermis. This is done using vacuum suction on the face while sandblasting the aluminum oxide crystals, basically on the skin. Microdermabrasion usually requires repeated treatments to maintain slight and temporary results.
レーザー、光源及びラジオ周波数治療。レーザーリサーファシングにおいて、レーザービームは、皮膚の外層（表皮）を破壊し、及び、皮膚の下層（真皮）に熱を加え、これは新しいコラーゲン線維の成長を刺激する。傷が治癒すると、滑らかで引き締まった新しい皮膚が形成する。完全に治癒するのに、レーザーリサーファシングから最大数カ月かかることもある。強さを抑えたレーザー（ノンアブレーティブ レーザー（ｎｏｎａｂｌａｔｉｖｅ ｌａｓｅｒｓ））、パルス光源及びラジオ周波数装置は、表皮を傷つけない。これらの治療は、真皮に熱を加え、新しいコラーゲン及びエラスチンを形成させる。数回の治療後、皮膚はしっかりとした感じになり、リフレッシュされる。これは短い回復時間を意味するが、通常、治療はより頻繁に繰り返す必要があり、結果はわずかなものである。 Laser, light source and radio frequency therapy. In laser resurfacing, the laser beam destroys the outer layer of the skin (the epidermis) and applies heat to the lower layer of the skin (the dermis), which stimulates the growth of new collagen fibers. As the wound heals, a new skin that is smooth and firm is formed. It can take up to several months after laser resurfacing to fully heal. Intense lasers (non-ablative lasers), pulsed light sources and radio frequency devices do not damage the epidermis. These treatments apply heat to the dermis to form new collagen and elastin. After several treatments, the skin feels firm and refreshes. This means a short recovery time, but usually the treatment needs to be repeated more frequently and the results are negligible.
ケミカルピーリング（Ｃｈｅｍｉｃａｌ ｐｅｅｌ）。患部に酸を塗布し、皮膚の外層を火傷させる。中深皮では、表皮全体と真皮の一部が除去される。その場所に新しい皮膚が形成する。通常、新しい皮膚は、古い皮膚に比べて滑らかでしわが少ない。発赤は数カ月続く。表面剥離では、表皮の一部のみが除去される。一連のピーリング後、肌の細かいしわが少なくなることがあり、茶色いしみが薄くなることがある。 Chemical peel. Apply acid to the affected area and burn the outer skin. In the middle deep skin, the entire epidermis and part of the dermis are removed. New skin forms at that location. New skin is usually smoother and less wrinkled than old skin. Redness continues for several months. In the surface peeling, only a part of the epidermis is removed. After a series of peels, fine wrinkles on the skin may be reduced and brown stains may become lighter.
ボツリヌス毒素タイプＡ（ボトックス）。特定の筋肉に少量を注射すると、ボトックスは筋収縮を引き起こす化学信号を阻害する。筋肉が収縮しないと、皮膚は平らになり、滑らかに見え、しわは少なくなる。ボトックスは、眉と額全体の間のしわ及び目尻のしわによく効く。通常、結果は約３〜４ヶ月続く。結果を維持するには注射を繰り返す必要がある。
軟部組織注入用製剤（Ｓｏｆｔ ｔｉｓｓｕｅ ｆｉｌｌｅｒｓ）。脂肪、コラーゲン及びヒアルロン酸を含む、軟部組織注入用製剤（Ｓｏｆｔ ｔｉｓｓｕｅ ｆｉｌｌｅｒｓ）は、顔のしわ深くに注入することができる。それらは肌をふっくらとさせ、しわ及び深いしわを伸ばし、皮膚にボリュームを与える。この手順は数カ月ごとに繰り返すことが必要な場合もある。
Botulinum toxin type A (Botox). When small amounts are injected into certain muscles, Botox inhibits chemical signals that cause muscle contraction. If the muscles do not contract, the skin becomes flat, looks smooth, and wrinkles are reduced. Botox works well on wrinkles between the eyebrows and the entire forehead and on the corners of the eyes. Usually the results last about 3-4 months. In order to maintain results, repeated injections are required.
Soft tissue fillers. Soft tissue fillers containing fat, collagen and hyaluronic acid can be injected deep into the wrinkles of the face. They make the skin plump, stretch wrinkles and deep wrinkles, and give the skin a volume. This procedure may need to be repeated every few months.
フェイスリフト。フェイスリフトの手順は、顔の下及び首及び下層にある筋肉及び結合組織の余分な皮膚及び脂肪の切除を含む。通常、結果は５〜１０年続く。フェイスリフト後の治療時間は長くかかることがある。通常、あざや腫れは術後２〜３週間ははっきりとしている。 Face lift. The face lift procedure involves excision of excess skin and fat in the muscles and connective tissue under the face and in the neck and underlying layers. The results usually last 5-10 years. Treatment time after a facelift may take a long time. Usually, bruises and swelling are evident for 2-3 weeks after surgery.
外科的処置は数多く存在し、且つ成功を収めているが、未だ欠点や手術の合併症を引き起こすことがあり、手術を繰り返さなければならないことがある。 Numerous surgical procedures exist and have been successful, but can still cause shortcomings and surgical complications and may require repeated surgery.
軟膏、クリーム、ローションなどの局所塗布は、作用に様々な状態がある。それでもこの分野は新しいアイディアに対して開かれている。 Topical applications such as ointments, creams and lotions have various states of action. Still, this area is open to new ideas.
新しい物質が創られ、有効性と、いかなる有害な合併症がないことが証明される度に、この分野の再建に良い科学的付加がされたとみなされる。 Each time a new substance is created and proven to be effective and free of any harmful complications, it is considered that a good scientific addition has been made to the reconstruction of this field.
傷及び皮膚の潰瘍は、治癒を促進する新物質を必要とする別の分野である。 Wounds and skin ulcers are another area that requires new substances that promote healing.
Ａ−しわは高齢化による自然なものであり、皮膚は薄くなり、乾燥し、弾力を失う。そして、皮膚はダメージから身を守ることができなくなる。結果として、肌にしわ、線及び溝ができる。遺伝的特徴は、肌の質感を決定する最も重要なものではあるが、しわの大きな引き金となるのは、太陽の下であまりに多くの時間を過ごすことにある。喫煙もまた肌の外観に悪影響を与えることがある。 A-wrinkles are natural due to aging, the skin becomes thin, dry and loses elasticity. And the skin can no longer protect itself from damage. As a result, the skin has wrinkles, lines and grooves. Genetic features are the most important factor in determining the texture of the skin, but the main trigger for wrinkles is in spending too much time in the sun. Smoking can also adversely affect the appearance of the skin.
しわは複数の要因の組み合わせにより引き起こされる。
年齢。年をとると、皮膚は自然と薄くなり、弾力を失い、より脆くなる。皮脂の減少は皮膚を乾燥させ、しわを増やす。皮膚にふっくらとした外観を与える皮膚の深い層の脂肪は減り始める。これが皮膚のゆるみや下垂及びはっきりしたしわ及び溝を引き起こす。
Wrinkles are caused by a combination of factors.
age. As you age, the skin naturally becomes thinner, loses elasticity, and becomes more brittle. The reduction of sebum dries the skin and increases wrinkles. The fat in the deep layers of the skin that gives the skin a plump appearance begins to decrease. This causes looseness and drooping of the skin and sharp wrinkles and grooves.
紫外（ＵＶ）線照射。紫外線は自然な老化プロセスを早め、早期のしわの主な原因となる。紫外線は結合組織―皮膚の深い層（真皮）にあるコラーゲン及びエラスチン線維を破壊する。結合組織の支えがないと、皮膚はその強さと柔軟性を失う。その結果、皮膚は下垂し始め、しわができやすくなる。 Ultraviolet (UV) radiation. Ultraviolet light accelerates the natural aging process and is a major cause of early wrinkles. Ultraviolet rays destroy connective tissue—collagen and elastin fibers in the deep layers of the skin (dermis). Without the support of connective tissue, the skin loses its strength and flexibility. As a result, the skin begins to droop and wrinkles easily.
喫煙。喫煙は、皮膚の通常の老化プロセスを加速させ、しわの原因となることがある。これはおそらく唇周辺の皮膚の血液供給量の変化が起因している。 smoking. Smoking accelerates the normal aging process of the skin and can cause wrinkles. This is probably due to changes in the blood supply of the skin around the lips.
Ｂ−以下の２つの物質が添加された基剤としての油性溶液（パラフィン、アーモンドオイル、蜜蝋、香料）中の７０％ワセリンからなる、２つの濃度の新しい軟膏（ＳＥ ＣＡＲＥ）。 B-Two concentrations of new ointment (SE CARE) consisting of 70% petrolatum in an oily solution (paraffin, almond oil, beeswax, fragrance) as a base with the following two substances added.
物質１：ビタミンＥは、８つの抗酸化物質群、４つのトコフェロール、アルファ−、ベータ−、ガンマ−及びデルタ−、及び４つのトコトリエノール（これも同様にアルファ−、ベータ−、ガンマ−、及びデルタ−）を表す。アルファ‐トコフェロールは人間の体内で活性を維持するビタミンＥの唯一の形であり、したがって、ビタミンＥのこの形は、血中及び組織中に最も数多く見つかる。人体におけるアルファ−トコフェロールの主な機能は、その抗酸化物質の機能であると思われる。フリーラジカルは正常な代謝中及び喫煙もしくは汚染物質のような環境要因に曝すと体内で主に形成される。脂肪は、全ての細胞膜に不可欠な部分であり、フリーラジカルによる酸化を介した破壊に弱い。脂溶性ビタミン、アルファ−トコフェロールは、フリーラジカルを阻害し、脂質破壊の連鎖反応を防ぐのに適している。全身の細胞膜の完全性を維持することを別としても、アルファ−トコフェロールは、低密度リポタンパク質（ｌｏｗ ｄｅｎｓｉｔｙ ｌｉｐｏｐｒｏｔｅｉｎｓ：ＬＤＬｓ）における脂肪も酸化から保護する。 Substance 1: Vitamin E contains eight antioxidant groups, four tocopherols, alpha-, beta-, gamma- and delta-, and four tocotrienols (also alpha-, beta-, gamma-, and delta). -). Alpha-tocopherol is the only form of vitamin E that remains active in the human body, and therefore this form of vitamin E is most frequently found in blood and tissues. The main function of alpha-tocopherol in the human body appears to be its antioxidant function. Free radicals are mainly formed in the body during normal metabolism and when exposed to environmental factors such as smoking or pollutants. Fat is an integral part of all cell membranes and is vulnerable to destruction through free radical oxidation. The fat-soluble vitamin, alpha-tocopherol, is suitable for inhibiting free radicals and preventing the chain reaction of lipid breakdown. Apart from maintaining systemic cell membrane integrity, alpha-tocopherol also protects fats in low density lipoproteins (LDLs) from oxidation.
物質２：化学的及び生物学的に４２．５ｍｇ／ｍｌに標準化された仔牛（Ｂｏｓ ｔａｕｒｕｓ：家畜種のウシ）血液のタンパク質を含まない血液透析物。これは、代謝活性化組織であり、化学的及び生物学的に脱タンパクに標準化され、健康な若いウシの血液から非抗原性および非発熱性に血液透析された抽出物である。これは、天然の低分子量物質−糖脂質、ヌクレオシド、ヌクレオチド、アミノ酸、オリゴペプチド、必須微量元素、電解質、炭水化物及び脂肪代謝の介在物質を多量に含む。これは、低酸素症の場合特に、ミトコンドリアの酸素吸収を増やすことで細胞の酸素消費を刺激し、代謝、グルコース輸送を正常化し、ＡＴＰ合成を刺激し、及び、可逆細胞及び組織の損傷の回復を加速させる。血管生成を刺激し、虚血組織の血行再建、コラーゲン合成のための条件をつくること、及び新しい肉芽組織の成長を促進し、及び、再生及び創傷の被覆を加速させる。膜安定化と細胞保護性を保持する。 Substance 2: Hemodialysate free of protein of calf (Bos taurus) blood chemically and biologically standardized to 42.5 mg / ml. It is a metabolically activated tissue, an extract that is chemically and biologically standardized for deproteinization and non-antigenic and non-pyrogenic hemodialyzed from healthy young bovine blood. It is rich in natural low molecular weight substances-glycolipids, nucleosides, nucleotides, amino acids, oligopeptides, essential trace elements, electrolytes, carbohydrates and mediators of fat metabolism. It stimulates cellular oxygen consumption by increasing mitochondrial oxygen absorption, normalizes metabolism, glucose transport, stimulates ATP synthesis, and restores reversible cell and tissue damage, particularly in the case of hypoxia Accelerate. Stimulates angiogenesis, promotes revascularization of ischemic tissue, creates conditions for collagen synthesis, promotes the growth of new granulation tissue, and accelerates regeneration and wound covering. Maintains membrane stabilization and cytoprotection.
Ｃ−低濃度のＳＥ ＣＡＲＥ軟膏は、皮膚を活性化し、及びしわを顕著に減少させる能力を有し、高濃度のＳＥ ＣＡＲＥ軟膏は、頭毛を成長させ、及び持続性潰瘍の治癒を促進する能力を有する。 C-low concentration SE CARE ointment has the ability to activate skin and significantly reduce wrinkles, high concentration SE CARE ointment grows hair and promotes healing of persistent ulcers Have the ability.
発明
軟膏基剤：（ＳＥ ＣＡＲＥ）以下の二つの物質を添加した基剤としての油性溶液（パラフィン、アーモンドオイル、蜜蝋、香料）中の７０％ワセリンからなる軟膏基剤。
ａ−物質１（ビタミンＥ）１ｇｍと物質２（化学的及び生物学的に４２．５ｍｇ／ｍｌに標準化された仔牛（家畜種のウシ）血液のタンパク質を含まない血液透析物）０．１ｇｍとを基剤軟膏１００ｇｍごとに添加することで新しい軟膏が作られ（ＳＥ ＣＡＲＥ１）、この軟膏は一日に一回皮膚に塗布されることで、３ヶ月以内に皮膚を再生し、及びシワを顕著に減らす能力を有するもの。
ｂ−物質１（ビタミンＥ）１ｇｍと物質２（化学的及び生物学的に４２．５ｍｇ／ｍｌに標準化された仔牛（家畜種のウシ）血液のタンパク質を含まない血液透析物）０．５ｇｍとを基剤軟膏１００ｇｍごとに添加することで新しい軟膏が作られ（ＳＥ ＣＡＲＥ２）、この軟膏は、一日に一回皮膚に塗布されることで、２週間で持続性潰瘍の治癒を促進し、３ヶ月で頭毛の成長を顕著に刺激する能力を有する。
Invention Ointment Base: (SE CARE) An ointment base comprising 70% petrolatum in an oily solution (paraffin, almond oil, beeswax, fragrance) as a base to which the following two substances are added.
a- Substance 1 (vitamin E) 1 gm and substance 2 (chemically and biologically standardized calf (domestic cattle) blood dialysate without hemoprotein dialysed to 42.5 mg / ml) 0.1 gm Is added every 100 gm of base ointment to create a new ointment (SE CARE 1). This ointment is applied to the skin once a day to regenerate the skin within 3 months, and notice wrinkles. Have the ability to reduce to
b-1 gm of substance 1 (vitamin E) and 0.5 gm of substance 2 (hemodialysate free from protein of calf (domestic cattle) blood standardized chemically and biologically to 42.5 mg / ml) and Is added every 100 gm of base ointment to create a new ointment (SE CARE2) that is applied to the skin once a day to promote healing of persistent ulcers in 2 weeks, Has the ability to significantly stimulate hair growth in 3 months.
化学式
Ａ−軟膏基剤：（ＳＥ ＣＡＲＥ）以下の二つの物質を添加した基剤としての油性溶液（パラフィン、アーモンドオイル、蜜蝋、香料）中の７０％ワセリンからなる軟膏基剤。
Chemical Formula A-Ointment Base: (SE CARE) An ointment base consisting of 70% petrolatum in an oily solution (paraffin, almond oil, beeswax, fragrance) as a base with the following two substances added.
Ｂ−物質１：ビタミンＥは８つの抗酸化物質群、４つのトコフェロール、アルファ−、ベータ−、ガンマ−及びデルタ−、及び４つのトコトリエノール（これも同様にアルファ−、ベータ−、ガンマ−、及びデルタ−）を表す。 B-Substance 1: Vitamin E contains eight antioxidant groups, four tocopherols, alpha-, beta-, gamma- and delta-, and four tocotrienols (also alpha-, beta-, gamma-, and Delta-).
Ｃ−物質２：化学的及び生物学的に４２．５ｍｇ／ｍｌに標準化された仔牛（家畜種のウシ）血液のタンパク質を含まない血液透析物。 C-Substance 2: Hemodialysate free of protein from calf (domestic cattle) blood, chemically and biologically standardized to 42.5 mg / ml.
新規の軟膏ＳＥ ＣＡＲＥ１及びＳＥ ＣＡＲＥ２は工業化され得る。 The new ointments SE CARE1 and SE CARE2 can be industrialized.
局所治療として使用される製品は、皮膚を再生し、及びしわを顕著に減少させる能力、持続性潰瘍の治癒を促進し、及び頭毛の成長を刺激する能力を有する。 Products used as topical treatments have the ability to regenerate skin and significantly reduce wrinkles, promote persistent ulcer healing, and stimulate hair growth.
Claims (3)
Ａ−物質１として記載のビタミンＥ（８つの抗酸化物質群、４つのトコフェロール、アルファ−、ベータ−、ガンマ−及びデルタ−、及び４つのトコトリエノール（これも同様にアルファ−、ベータ−、ガンマ−、及びデルタ−））
Ｂ−物質２として記載の、化学的及び生物学的に４２．５ｍｇ／ｍｌに標準化された仔牛（Ｂｏｓ ｔａｕｒｕｓ：家畜種のウシ）血液のタンパク質を含まない血液透析物
局所用製剤に共に用いられた場合、３ヶ月で皮膚を活性化し、しわを減らし、髪の成長を刺激し、且つ２週間で持続性潰瘍の治癒を促進する能力を有するものである、物質。 Two different substances,
A-vitamin E described as substance 1 (8 antioxidant groups, 4 tocopherols, alpha-, beta-, gamma- and delta-, and 4 tocotrienols (also alpha-, beta-, gamma- And delta-))
B-Substance 2 chemically and biologically standardized to 42.5 mg / ml of calf (Bos taurus) blood protein free hemodialysate used together with topical preparations A substance that has the ability to activate the skin in 3 months, reduce wrinkles, stimulate hair growth and promote healing of persistent ulcers in 2 weeks.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2008010173 | 2008-01-30 | ||
| PCT/EG2008/000010 WO2009095028A1 (en) | 2008-01-30 | 2008-02-21 | Ointment on the basis of a dialysate of calves' blood. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2011510935A true JP2011510935A (en) | 2011-04-07 |
Family
ID=40912296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010544583A Withdrawn JP2011510935A (en) | 2008-01-30 | 2008-02-21 | Novel ointment to promote skin activation and ulcer healing |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2240188A4 (en) |
| JP (1) | JP2011510935A (en) |
| WO (1) | WO2009095028A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456166A (en) * | 2015-12-21 | 2016-04-06 | 太仓张根木生物科技有限公司 | Anti-wrinkle moisturizing toner |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2757937A1 (en) * | 1977-12-24 | 1979-06-28 | Byk Gulden Lomberg Chem Fab | Skin-care cosmetics - contg. calf's blood haemodialysate |
| DE3042999C2 (en) * | 1980-11-14 | 1984-05-10 | Solco Basel AG, Birsfelden | Process for the production of a skin cosmetic |
| JPS63135309A (en) * | 1986-11-28 | 1988-06-07 | Shiseido Co Ltd | Skin external preparation |
| JP3001942B2 (en) * | 1990-08-07 | 2000-01-24 | 鐘紡株式会社 | Skin cosmetics |
| DE4113346A1 (en) * | 1991-04-24 | 1992-10-29 | Lang Erich | Aq. lotion for strengthening and regeneration of hair-growth - comprises ethanol@, phospholipid(s) (derived from soya bean oil) oil, and/or grease |
| JP3202810B2 (en) * | 1992-10-15 | 2001-08-27 | 協和醗酵工業株式会社 | Cosmetics |
| EP0645135A1 (en) * | 1993-09-29 | 1995-03-29 | Solco Basel AG | Sunscreen composition containing hemodialysate |
| DE10156297A1 (en) * | 2001-11-19 | 2003-05-28 | Henkel Kgaa | Skin protectant, especially hand cream, which remains in place for long periods comprising paraffin oils, petrolatum, carnauba wax and optionally silicon oils and/or additional waxes |
| US20040191196A1 (en) * | 2002-12-16 | 2004-09-30 | Dov Tamarkin | Novel conjugate compounds and dermatological compositions thereof |
| US20060134046A1 (en) * | 2004-12-21 | 2006-06-22 | Ibrahim Hanna | Skin nourishing and moisturizing cream |
-
2008
- 2008-02-21 EP EP08706951.4A patent/EP2240188A4/en not_active Withdrawn
- 2008-02-21 JP JP2010544583A patent/JP2011510935A/en not_active Withdrawn
- 2008-02-21 WO PCT/EG2008/000010 patent/WO2009095028A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| EP2240188A1 (en) | 2010-10-20 |
| WO2009095028A1 (en) | 2009-08-06 |
| EP2240188A4 (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ortonne et al. | Melanin pigmentary disorders: treatment update | |
| Farris | Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions | |
| Ehrlich et al. | Improvement in the appearance of wrinkles with topical transforming growth factor β1 and L-ascorbic acid | |
| Block et al. | Emerging therapies for scar prevention | |
| Rokhsar et al. | Review of photorejuvenation: devices, cosmeceuticals, or both? | |
| BR112018015897B1 (en) | Anhydrous topical composition to promote skin repair, topical compositions to promote skin restoration, topical composition to relieve bruises caused by a cosmetic procedure and use thereof | |
| JP2011525116A (en) | Nitric oxide device and method of healing wounds, treating skin disorders and microbial infections | |
| KR100673044B1 (en) | The composition for external use by percutaneous administration | |
| US9585830B2 (en) | Vitamin C composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same | |
| US6630442B1 (en) | Reparatives for chemosurgery and laser (thermal) therapy | |
| US20100098732A1 (en) | Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or aging skin, and/or hair loss | |
| JP2011510935A (en) | Novel ointment to promote skin activation and ulcer healing | |
| CN113693966B (en) | Whitening spot-lightening and brightening cream and preparation method thereof | |
| RU2736504C1 (en) | System of transdermal transfer enhancers and cosmetic compositions based thereon | |
| Konda et al. | Age reversing modalities: An overview | |
| RU2370275C2 (en) | Method of cosmetic and age skin defect treatment (correction) at combined application of fraction photothermolysis technology with bioactive ingredients independently of administration method | |
| Ding et al. | Application of integrated skincare in medical aesthetics: A literature review | |
| CA3091879A1 (en) | Regenerating composition with smoothing action for treating skin imperfections and process for preparation thereof | |
| US8969411B2 (en) | Vitamin C composition for use in the prevention and treatment of stretch other skin conditions and methods of using the same | |
| Chernoff | A novel combination therapy in aesthetic and reconstructive surgery: sea salt, exfoliation, cavitating ultrasound, and high intensity multiwavelength LED treatment:(SaltFacial) | |
| TWM656940U (en) | Liposome-coated structure with plant-derived bioactive peptides | |
| Corsetti et al. | Aging Skin: Nourishing from Out-In. Lessons from Wound Healing | |
| EP4085913A1 (en) | Formulation comprising nicotinamide, zinc, copper and glutathione for treating acne rosacea | |
| Khan et al. | Cosmeceuticals: The Fusion of Beauty and Science | |
| Fernandes | Understanding and treating photoaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A300 | Application deemed to be withdrawn because no request for examination was validly filed |
Free format text: JAPANESE INTERMEDIATE CODE: A300 Effective date: 20110510 |